BrainStorm (BCLI) – Bone Marrow Stem Cell Co. Profile Released

In BUSINESS OF STEM CELLS on August 27, 2009 at 8:42 am

Bone Marrow Stem Cell Company Profile Released

LAS VEGAS, Aug. 27, 2009 (GLOBE NEWSWIRE) — A report addressing one company’s research using human bone marrow stem cells has been released. The report will explore the efforts of BrainStorm (OTCBB:BCLI) and is of interest to investors of leading stem cell equities Geron (Nasdaq:GERN), Osiris Therapeutics (Nasdaq:OSIR), Aastrom Biosciences (Nasdaq:ASTM) and StemCells (Nasdaq:STEM).

From the report: BrainStorm (OTCBB:BCLI) is a leading developer of stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing NTF cells from the patient’s own bone marrow in order to treat, Parkinson, ALS, and Spinal Cord Injury.

The adult stem cells are used to create healthy NTF cells which produce and secrete neurotrophic factors, which are essential for the survival and outgrowth of neurons, and may become beneficial in neurodegenerative diseases. Patients treated with the Company’s NurOwn(tm) therapeutic cells are expected to enjoy a rapid recovery and much enhanced quality of life. BrainStorm’s therapy has the potential to cure underlying pathology, rather than simply treat symptoms. BrainStorm’s management and scientific teams are passionately devoted to the Company’s mission: regenerating the mind… in their lifetime.

via SmallCapSentinel.com: Bone Marrow Stem Cell Company Profile Released.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: